ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

Prescriber Checkup » Louisiana » Hematology Oncology

Top Hematology Oncology Prescribers in Louisiana

Top Prescribers

Providers are grouped by the primary specialty they listed when applying for a national health ID number. This doesn’t necessarily mean the person has special training or certification. Specialty is self-reported by providers and may have changed. Patients and claims shown are for Medicare Part D only.

Prescriber Claims Filled Total Cost Medicare Part D Patients Claims for Brand Name Drugs Schedule Two Schedule Three Dangerous Drugs to Seniors Brand Name Drugs Prescription Price
JOSE LEFRAN M.D

Hematology Oncology

13,600

$670K

869
707 are 65+

3%
patients receiving schedule two controlled substances

Avg: 14%

13%
patients receiving schedule three controlled substances

Avg: 15%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

22%
prescriptions for brand name drugs

Avg: 18%

$49
Average prescription price

Avg: $342

MAHESH PANDYA M.D.

Hematology Oncology

6,802

$649K

240
209 are 65+

5%
patients receiving schedule two controlled substances

Avg: 14%

27%
patients receiving schedule three controlled substances

Avg: 15%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

32%
prescriptions for brand name drugs

Avg: 18%

$95
Average prescription price

Avg: $342

JAMES GAHARRAN M.D.

Hematology Oncology

3,435

$410K

273
219 are 65+

14%
patients receiving schedule two controlled substances

Avg: 14%

26%
patients receiving schedule three controlled substances

Avg: 15%

6%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

19%
prescriptions for brand name drugs

Avg: 18%

$119
Average prescription price

Avg: $342

HOWARD WOLD M.D.

Hematology Oncology

3,007

$575K

261
218 are 65+

10%
patients receiving schedule two controlled substances

Avg: 14%

17%
patients receiving schedule three controlled substances

Avg: 15%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

23%
prescriptions for brand name drugs

Avg: 18%

$191
Average prescription price

Avg: $342

MANISH DHAWAN MD

Hematology Oncology

2,904

$2.45M

368
320 are 65+

8%
patients receiving schedule two controlled substances

Avg: 14%

12%
patients receiving schedule three controlled substances

Avg: 15%

6%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

28%
prescriptions for brand name drugs

Avg: 18%

$843
Average prescription price

Avg: $342

DAVID RINALDI M.D.

Hematology Oncology

2,827

$1.01M

326
248 are 65+

10%
patients receiving schedule two controlled substances

Avg: 14%

17%
patients receiving schedule three controlled substances

Avg: 15%

8%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

26%
prescriptions for brand name drugs

Avg: 18%

$358
Average prescription price

Avg: $342

HENRY GOOLSBY M.D.

Hematology Oncology

2,715

$389K

155
105 are 65+

18%
patients receiving schedule two controlled substances

Avg: 14%

35%
patients receiving schedule three controlled substances

Avg: 15%

4%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

22%
prescriptions for brand name drugs

Avg: 18%

$143
Average prescription price

Avg: $342

GERALD MILETELLO MD

Hematology Oncology

2,671

$851K

339
304 are 65+

11%
patients receiving schedule two controlled substances

Avg: 14%

17%
patients receiving schedule three controlled substances

Avg: 15%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

18%
prescriptions for brand name drugs

Avg: 18%

$319
Average prescription price

Avg: $342

MILTON SEILER MD

Hematology Oncology

2,662

$1.03M

257
203 are 65+

13%
patients receiving schedule two controlled substances

Avg: 14%

18%
patients receiving schedule three controlled substances

Avg: 15%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

27%
prescriptions for brand name drugs

Avg: 18%

$386
Average prescription price

Avg: $342

KAREN RODEN M.D.

Hematology Oncology

2,636

$1.18M

312
252 are 65+

6%
patients receiving schedule two controlled substances

Avg: 14%

13%
patients receiving schedule three controlled substances

Avg: 15%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

23%
prescriptions for brand name drugs

Avg: 18%

$449
Average prescription price

Avg: $342

JAMES CARINDER DO

Hematology Oncology

2,551

$937K

309
235 are 65+

19%
patients receiving schedule two controlled substances

Avg: 14%

23%
patients receiving schedule three controlled substances

Avg: 15%

5%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

20%
prescriptions for brand name drugs

Avg: 18%

$367
Average prescription price

Avg: $342

BURKE BROOKS M.D.

Hematology Oncology

2,397

$833K

232
196 are 65+

13%
patients receiving schedule two controlled substances

Avg: 14%

12%
patients receiving schedule three controlled substances

Avg: 15%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

18%
prescriptions for brand name drugs

Avg: 18%

$348
Average prescription price

Avg: $342

JACK SAUX MD

Hematology Oncology

2,313

$1.14M

314
250 are 65+

19%
patients receiving schedule two controlled substances

Avg: 14%

23%
patients receiving schedule three controlled substances

Avg: 15%

5%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

21%
prescriptions for brand name drugs

Avg: 18%

$491
Average prescription price

Avg: $342

MARSHALL STAGG MD

Hematology Oncology

2,260

$1.01M

255
203 are 65+

12%
patients receiving schedule two controlled substances

Avg: 14%

20%
patients receiving schedule three controlled substances

Avg: 15%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

18%
prescriptions for brand name drugs

Avg: 18%

$447
Average prescription price

Avg: $342

THOMAS COSGRIFF MD

Hematology Oncology

2,236

$603K

239
197 are 65+

28%
patients receiving schedule two controlled substances

Avg: 14%

10%
patients receiving schedule three controlled substances

Avg: 15%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

21%
prescriptions for brand name drugs

Avg: 18%

$270
Average prescription price

Avg: $342

JAMES COLE M.D.

Hematology Oncology

2,224

$1.19M

317
255 are 65+

11%
patients receiving schedule two controlled substances

Avg: 14%

12%
patients receiving schedule three controlled substances

Avg: 15%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

18%
prescriptions for brand name drugs

Avg: 18%

$535
Average prescription price

Avg: $342

ROBERT VEITH M.D.

Hematology Oncology

2,147

$1.28M

339
282 are 65+

20%
patients receiving schedule two controlled substances

Avg: 14%

16%
patients receiving schedule three controlled substances

Avg: 15%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

19%
prescriptions for brand name drugs

Avg: 18%

$598
Average prescription price

Avg: $342

RUBEN FABREGA MD

Hematology Oncology

2,057

$426K

244
210 are 65+

10%
patients receiving schedule two controlled substances

Avg: 14%

10%
patients receiving schedule three controlled substances

Avg: 15%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

16%
prescriptions for brand name drugs

Avg: 18%

$207
Average prescription price

Avg: $342

MICHAEL CASTINE MD

Hematology Oncology

2,050

$589K

222
184 are 65+

12%
patients receiving schedule two controlled substances

Avg: 14%

17%
patients receiving schedule three controlled substances

Avg: 15%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

19%
prescriptions for brand name drugs

Avg: 18%

$287
Average prescription price

Avg: $342

BRYAN BIENVENU MD

Hematology Oncology

1,980

$756K

207
157 are 65+

22%
patients receiving schedule two controlled substances

Avg: 14%

26%
patients receiving schedule three controlled substances

Avg: 15%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

21%
prescriptions for brand name drugs

Avg: 18%

$382
Average prescription price

Avg: $342

JOHN COLE MD

Hematology Oncology

1,964

$462K

219
185 are 65+

14%
patients receiving schedule two controlled substances

Avg: 14%

11%
patients receiving schedule three controlled substances

Avg: 15%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

20%
prescriptions for brand name drugs

Avg: 18%

$235
Average prescription price

Avg: $342

ANIL VELUVOLU MD

Hematology Oncology

1,932

$678K

257
198 are 65+

19%
patients receiving schedule two controlled substances

Avg: 14%

26%
patients receiving schedule three controlled substances

Avg: 15%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

20%
prescriptions for brand name drugs

Avg: 18%

$351
Average prescription price

Avg: $342

JAMES ELLIS M.D.

Hematology Oncology

1,929

$734K

247
206 are 65+

11%
patients receiving schedule two controlled substances

Avg: 14%

21%
patients receiving schedule three controlled substances

Avg: 15%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

16%
prescriptions for brand name drugs

Avg: 18%

$381
Average prescription price

Avg: $342

SCOTT SONNIER MD

Hematology Oncology

1,791

$875K

247
211 are 65+

10%
patients receiving schedule two controlled substances

Avg: 14%

12%
patients receiving schedule three controlled substances

Avg: 15%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

20%
prescriptions for brand name drugs

Avg: 18%

$489
Average prescription price

Avg: $342

JOSEPH BRIERRE M.D.

Hematology Oncology

1,771

$548K

256
223 are 65+

11%
patients receiving schedule two controlled substances

Avg: 14%

22%
patients receiving schedule three controlled substances

Avg: 15%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

13%
prescriptions for brand name drugs

Avg: 18%

$309
Average prescription price

Avg: $342

Sources

Centers for Medicare and Medicaid Services; National Technical Information Service; First Databank